A Phase II Study of Navarixin (MK-7123) in Combination with Pembrolizumab (MK-3475) in Participants with Selected Advanced/Metastatic Solid Tumors
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Start Date
June 18, 2018
End Date
April 26, 2022
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Start Date
June 18, 2018
End Date
April 26, 2022